Saying goodbye to R&D chief, Flagship-backed Axcella drops PhII program as it focuses on long Covid, NASH
In its bid to be one of the first biotechs to develop a drug for long Covid, which impacts as many as 1 in 4 elder Americans, Axcella said Thursday it has completed enrollment in a Phase IIa study looking at fatigue-related lingering symptoms of the pandemic disease.
But the company will have to make progress with its long Covid and NASH mid-stage programs without its president of R&D, Alison Schecter. She stepped down immediately yesterday to “pursue other opportunities” after 14 months with the Flagship-founded biotech, according to an SEC filing, and Axcella doesn’t currently have plans to replace her, CEO Bill Hinshaw told Endpoints News in an emailed statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.